MarketCap
Facebook
X
TelegramQuartalsbericht 2023-Q1
hinzugefügt 15.05.2023
Novan Operativer Cashflow 2011-2026 | NOVN
Operativer Cashflow Jährlich Novan
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -30.9 M | -24.8 M | -31.1 M | -19.9 M | -28.6 M | -29.9 M | -49.2 M | -22.2 M | -8.6 M | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -8.6 M | -49.2 M | -27.2 M |
Operativer Cashflow Vierteljährlich Novan
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.25 M | - | -19.8 M | -10.3 M | 766 K | - | -16 M | -11 M | -8.6 M | - | -21.9 M | -13.8 M | -7.44 M | - | -11.4 M | -926 K | -2.11 M | - | -24.9 M | -16.5 M | -9.65 M | - | -21.9 M | -14.4 M | -3.96 M | - | -32.6 M | -22.3 M | -9.48 M | - | -14.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 766 K | -32.6 M | -12.9 M |
Operativer Cashflow anderer Aktien in der Pharmaeinzelhändler
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
-12.3 M | $ 3.97 | 6.43 % | $ 9.55 B |  Australia |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M |  USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
-38.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M | France |
 |
Akari Therapeutics, Plc
AKTX
|
-10.6 M | $ 5.12 | 11.55 % | $ 345 B |  Britain |
 |
Aligos Therapeutics
ALGS
|
-82.5 M | $ 7.66 | 3.23 % | $ 75.7 M | USA |
 |
Allakos
ALLK
|
-116 M | - | - | $ 28.6 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
524 M | $ 320.13 | -3.98 % | $ 41.9 B | USA |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
156 M | $ 21.81 | 0.6 % | $ 1.02 B | USA |
 |
Burford Capital Limited
BUR
|
181 M | $ 4.67 | -1.37 % | $ 766 M | Britain |
 |
Applied Therapeutics
APLT
|
-55.2 M | - | - | $ 8.42 M | USA |
 |
BioNTech SE
BNTX
|
890 M | $ 102.12 | 2.66 % | $ 27.2 B | Germany |
 |
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M |  Canada |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.95 M | $ 3.08 | -4.94 % | $ 5.07 M |  Israel |
 |
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
68 M | $ 1.35 | -12.9 % | $ 347 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M | Israel |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
-52.4 M | $ 4.26 | 0.47 % | $ 456 M | USA |
 |
AstraZeneca PLC
AZN
|
5.96 B | - | - | $ 96.9 B | Britain |
 |
Arcutis Biotherapeutics
ARQT
|
-5.62 M | $ 24.19 | -1.59 % | $ 3.08 B | USA |
 |
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-6.98 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
41 M | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-284 M | $ 1.61 | 8.05 % | $ 428 M | Britain |
 |
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | Canada |
 |
AVROBIO
AVRO
|
-63.2 M | - | 1083.1 % | $ 745 M | USA |
 |
BeiGene, Ltd.
BGNE
|
1.13 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
-235 M | - | - | $ 546 M | USA |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Cidara Therapeutics
CDTX
|
-177 M | - | - | $ 1.41 B | USA |
 |
BioXcel Therapeutics
BTAI
|
-57.6 M | $ 1.07 | 1.9 % | $ 13.1 M | USA |
 |
Cabaletta Bio
CABA
|
-131 M | $ 3.52 | 3.53 % | $ 354 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-72.5 M | - | - | $ 3.45 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
ChromaDex Corporation
CDXC
|
13.5 M | - | -0.88 % | $ 598 M | USA |